Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515555 | 0.94 | MEN1 (0.56) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL6516714 | 0.84 | GSK3B (0.54) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL6518138 | 0.84 | GSK3B (0.56) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL6522334 | 0.82 | GSK3B (0.56) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL10647724 | 0.75 | KDM4E (0.63) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL6519951 | 0.75 | GSK3B (0.58) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL11375916 | 0.75 | KDM4E (0.61) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL6521717 | 0.71 | GSK3B (0.49) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL23510959 | 0.71 | GRIN2D (0.58) | MEN1ALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL23511153 | 0.71 | ALDH1A1 (0.66) | MEN1ALDH1A1MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | MEN1 1973/4885ALDH1A1 4635/4885MAPT 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.